Immunoassays | Inflammation & Cytokines

Erenna® IL-21 Immunoassay Kit (Cat# 03-0014-xx)

download PDF data sheet

download PDF package insert

Introduction

The Erenna® IL-21 Immunoassay Kit uses a quantitative fluorescent sandwich immunoassay technique to measure IL-21 in human K2 EDTA plasma samples. A capture antibody specific for IL-21 has been pre-coated onto paramagnetic microparticles (MP). The user pipettes MP, standards, and samples into uncoated microplate wells. During incubation, the IL-21 present in the sample binds to the capture antibody on the coated MP. Unbound molecules are washed away during the subsequent buffer exchange and wash steps. Fluor-labeled detection antibody is added to each well and incubated. This detection antibody recognizes and binds to IL-21 that has been captured onto the MP. During the following wash step the MPs are transferred to a clean plate. Elution buffer is then added and incubated. The elution buffer dissociates the bound protein sandwich from the MP surface, releasing the labeled antibodies. These antibodies are separated during transfer to a final microplate. The plate is loaded into the Erenna System where the labeled molecules are detected and counted. The number of fluor-labeled detection antibodies counted is directly proportional to the amount of IL-21 present in the sample when captured. The amount of IL-21 in unknown samples is interpolated from a standard curve.

Assay Performance

¹ See product insert for updated values
² LLoQ = 20% CV and ± 20% recovery
³ based upon median [IL-21] in a healthy reference

FIGURE 1. [IL-21] in serum from 19 healthy donors, with median and interquartile range. The Erenna® IL-21 Immunoassay Kit reliably quantifies IL-21 in serum from healthy subjects, who have a median [IL-21] of 0.53 pg/mL that is well above the detection limit of 0.005 pg/mL.

FIGURE 2. IL-21 assay low-end standard curve signal (left) and curve fit (right).

Representative data shown for demonstration purposes only. Individual results may vary depending upon samples tested and protocol used.

Biology and Disease

Interleukin-21 (IL-21) is a cytokine with a potent regulatory effect on the immune system. Mainly produced by activated T-cells, IL-21 is responsible for the hematopoiesis of T-, B-, natural killer and dendritic cells. The production and differentiation of these effector cells may lead to an increased immunity against cancerous or virally infected cells. Thus, the role of IL-21 in the regulation of immuno-inflammatory responses has important implications for diseases such as multiple sclerosis, metastatic melanoma and metastatic renal cell carcinoma. Thus IL-21 will remain an attractive subject for drug development. Successful study outcomes will further establish IL-21 immunotherapy as an effective treatment for various cancers and inflammatory diseases.

* Source Info from www.uniprot.org.

Related Products